Characteristics of patients with cystic fibrosis-dependent diabetes mellitus in childhood according to the register of patients with cystic fibrosis of the Russian Federation in 2021

BACKGROUND: In recent decades, the life expectancy of patients with CF has increased, which leads to an increase in the frequency of conditions associated with impaired carbohydrate metabolism.

AIM: to analyze the impact of cystic fibrosis-associated diabetes mellitus (CFDM) in children and adolescents on the course of cystic fibrosis according to the 2021 register of patients with cystic fibrosis of the Russian Federation (RF).

MATERIALS AND METHODS: the data of the register of patients with cystic fibrosis of the Russian Federation for 2021 were analyzed. The study included 122 patients with diabetes mellitus requiring the use of insulin — 33 children (27%) and 89 adults (73%), the average age of children was 13.5±4.1, the average age of adult.

patients aged 18 years and older was 27.4±6.6. To compare the course of cystic fibrosis in patients with and without diabetes mellitus, groups were formed that were comparable in age, gender, genotype — the group of patients without diabetes included 827 patients, 33 patients made up the group of patients with CFRD using insulin. Diagnostic criteria, indicators of respiratory function, microbiological status, nature of complications, volume of therapy were compared.

RESULTS: Patients with CFRD have a lower FEV1 compared to children without diabetes mellitus — M±SD FEV1 (%) 85.2±27.5 in the group of patients without diabetes mellitus and M±SD FEV1 (%) 72.4±26.0 in patients with diabetes mellitus (p < 0.016), compared in the microbiological seeding groups — a trend towards more frequent chronic growth of Pseudomonas aeruginosa 54.50% versus 39.4% in the group without CFRD. An increase in MRSA was also more often detected — 9.1% compared with the group of children without diabetes — 3.1%. Antibacterial therapy is more commonly used — inhaled in 54.6% of patients without diabetes mellitus while children with CFRD received inhaled antibiotic therapy in 75.8% (p=0.017). There was a significant difference in the used antibacterial tablet therapy (p=0.013). A significant difference in the number of patients on oxygen therapy in the group with CFRD — 12.1%, versus 3.4% without CFRD (p=0.01) confirms a more severe course of cystic fibrosis in patients with CFRD.

CONCLUSION: The prevalence of CFDM with the need for insulin therapy among children in the Russian Federation is 1.3%. Cystic fibrosis-associated diabetes mellitus significantly worsens the course of cystic fibrosis in terms of lung function, the growth of gram-negative and resistant flora, the presence of severe complications and the frequent use of antibiotic therapy, which is obviously associated with frequent exacerbations of the bronchopulmonary process in cystic fibrosis in patients with developed cystic fibrosis-associated diabetes mellitus.

1. Rana M, Munns CF, Selvadurai HC, et al. Increased detection of cystic-fibrosis-related diabetes in Australia. Arch Dis Child. 2011;96(9):823-826. doi: https://doi.org/10.1136/adc.2010.208652

2. Kern AS, Prestridge AL. Improving screening for cystic fibrosis-related diabetes at a pediatric cystic fibrosis program. Pediatrics. 2013;132(2):512-518. doi: https://doi.org/10.1542/peds.2012-4029

3. Scheuing N, Holl RW, Dockter G, et al. Diabetes in cystic fibrosis: multicenter screening results based on current guidelines. PLoS One. 2013;8(12):e81545. doi: https://doi.org/10.1371/journal.pone.0081545

4. Moran A, Becker D, Casella SJ, et al. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care. 2010;33(12):2677-2683. doi: https://doi.org/10.2337/dc10-1279

5. Chan CL, Vigers T, Pyle L. Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline. J. Cyst. Fibros. 2018;17(6):783-790. doi: https://doi.org/10.1016/j.jcf.2018.03.008

6. Ode KL, Frohnert B, Laguna T. Oral glucose tolerance testing in children with cystic fibrosis. Pediatr Diabetes. 2010;11(7):487-492. doi: https://doi.org/10.1111/j.1399-5448.2009.00632.x

7. Hart NJ, Aramandla R, Poffenberger G. Cystic fibrosis-related diabetes is caused by islet loss and inflammation. JCI Insight. 2018;3(8):e98240. doi: https://doi.org/10.1172/jci.insight.98240

8. Patient-Registry-Annual-Data-Report [cited 10.10.2023]. Available from: https://www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf

9. Sheikh S, Gudipaty L, De Leon DD. Reduced p-Cell Secretory Capacity in Pancreatic-Insufficient, but Not Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance. Diabetes. 2017;66(1):134-144. doi: https://doi.org/10.2337/db16-0394

10. Shwachman H, Leubner H. Mucoviscidosis. Advan Pediat. 1955;(7):249-323.

11. Middleton PG, Wagenaar M, Matson AG, et al. Australian standards of care for cystic fibrosis-related diabetes. Respirology. 2014;19(2):185-192. doi: https://doi.org/10.1111/resp.12227

12. Prentice BJ, Chelliah A, Ooi CY, et al. Peak OGTT glucose is associated with lower lung function in young children with cystic fibrosis. J Cyst Fibros. 2020;19(2):305-309. doi: https://doi.org/10.1016/j.jcf.2019.05.005

13. Lanng S, Thorsteinsson B, Nerup J, Koch C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr. 1992;151(9):684-687. doi: https://doi.org/10.1007/BF01957574

14. Доступно по: http://audit-orfan.clin-reg.ru/nozologii/mukoviscidoz.html.European Ссылка активна на 03.10.2023.

15. Cystic Fibrosis Society [Internet] Available from: https://www.ecfs.eu/ecfspr

16. Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care 11-th edition. Moscow: Ministerstvo zdravookhraneniia RF; 2023. (In Russ.). doi: https://doi.org/10.14341/DM13042

17. Neder JA. The new ERS/ATS standards on lung function test interpretation: some extant limitations. Eur Respir J. 2022;60(2):2200252. doi: https://doi.org/10.1183/13993003.00252-2022

18. Kondrat'eva EI, Kashirskaia NIu, Kapranov NI. Natsional'nyi konsensus. Mukovistsidoz: opredelenie, diagnosticheskie kriterii, terapiia. Moscow: Rossiiskoe obshchestvo meditsinskikh genetikov; 2016. 205 p. (In Russ.).

19. Polikarpova SV, Zhilina SV, Kondratenko OV. Guidelines for the microbiological diagnosis of respiratory tract infections in patients with cystic fibrosis. Moscow: Triada; 2019. (In Russ.).

20. Methods of bacteriological research of conditionally pathogenic microorganisms in clinical microbiology. Guidelines [cited 17.07.2022]. Available from: https://files.stroyinf.ru/Index2/1/4293727/4293727337.htm

21. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis—state of the art: Cystic fibrosis foundation consensus conference. Clin Infect Dis. 2003;37(S3):S225-S264. doi: https://doi.org/10.1086/376525

22. Moran A, Dunitz J, Nathan B. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32(9):1626-1631. doi: https://doi.org/10.2337/dc09-0586

23. Zorron Mei Hsia Pu M, Goncalves AC, et al. Continuous glucose monitoring to evaluate glycaemic abnormalities in cystic fibrosis. Arch Dis Child. 2018;103(6):592-596. doi: https://doi.org/10.1136/archdischild-2017-314250

24. Clemente Leon M, Bilbao Gasso L, Moreno-Galdo A. Oral glucose tolerance test and continuous glucose monitoring to assess diabetes development in cystic fibrosis patients. Endocrinol Diabetes Nutr. 2018;65(1):45-51. doi: https://doi.org/10.1016/j.endinu.2017.08.008

25. Leclercq A., Gauthier B., Rosner V. Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients. J Cyst Fibros. 2014;13(4):478-84. doi: https://doi.org/10.1016/j.jcf.2013.11.005

26. Kashirskaia NIu, Kapranova NI, Kondrat'eva EI. Mukovistsidoz. Izdanie 2-e., pererabotannoe i dopolnennoe. Moscow: Medpraktika; 2021. (In Russ.).

27. Samoilenko VA, Krasovski! SA, Marchenkov IV, et al. The clinical features of cystic fibrosis in adult patients with carbohydrate metabolic disturbances. Therapeutic Archive. 2013;85(3):32-37. (In Russ.).